gellerbiopharm.com
Geller Biopharm News: In The Press
http://www.gellerbiopharm.com/news_in_the_press.html
Geller Biopharm Inc Advises Ovid on Licensing Agreement with Lundbeck. April 15, 2015. Lundbeck and Ovid Therapeutics Announce Exclusive Worldwide Licensing Agreement for Gaboxadol Ovid plans to commence Phase 2 trials in two orphan neurological indications, Angelman Syndrome and Fragile X Syndrome, in 2016 NEW YORK and VALBY, Denmark- (BUSINESS WIRE)- H. Lundbeck A/S (Lundbeck; LUN.CO, LUN DC, HLUYY), A global pharmaceutical company specialized in brain diseases. We are happy with this agreement allowin...
gellerbiopharm.com
Geller Biopharm News: Press Releases
http://www.gellerbiopharm.com/news_press_releases.html
Geller Biopharm Inc Advises Ovid on Licensing Agreement with Lundbeck. April 15, 2015. Lundbeck and Ovid Therapeutics Announce Exclusive Worldwide Licensing Agreement for Gaboxadol Ovid plans to commence Phase 2 trials in two orphan neurological indications, Angelman Syndrome and Fragile X Syndrome, in 2016 NEW YORK and VALBY, Denmark- (BUSINESS WIRE)- H. Lundbeck A/S (Lundbeck; LUN.CO, LUN DC, HLUYY), A global pharmaceutical company specialized in brain diseases. We are happy with this agreement allowin...
gellerbp.com
Geller Biopharm News: Press Releases
http://www.gellerbp.com/news_press_releases.html
Geller Biopharm Inc Advises Ovid on Licensing Agreement with Lundbeck. April 15, 2015. Lundbeck and Ovid Therapeutics Announce Exclusive Worldwide Licensing Agreement for Gaboxadol Ovid plans to commence Phase 2 trials in two orphan neurological indications, Angelman Syndrome and Fragile X Syndrome, in 2016 NEW YORK and VALBY, Denmark- (BUSINESS WIRE)- H. Lundbeck A/S (Lundbeck; LUN.CO, LUN DC, HLUYY), A global pharmaceutical company specialized in brain diseases. We are happy with this agreement allowin...
gellerbp.com
Geller Biopharm News: In The Press
http://www.gellerbp.com/news_in_the_press.html
Geller Biopharm Inc Advises Ovid on Licensing Agreement with Lundbeck. April 15, 2015. Lundbeck and Ovid Therapeutics Announce Exclusive Worldwide Licensing Agreement for Gaboxadol Ovid plans to commence Phase 2 trials in two orphan neurological indications, Angelman Syndrome and Fragile X Syndrome, in 2016 NEW YORK and VALBY, Denmark- (BUSINESS WIRE)- H. Lundbeck A/S (Lundbeck; LUN.CO, LUN DC, HLUYY), A global pharmaceutical company specialized in brain diseases. We are happy with this agreement allowin...
SOCIAL ENGAGEMENT